Clinical features and outcome of COVID‐19 positive children from a tertiary healthcare hospital in Karachi. Issue 10 (14th July 2021)

• Record Type: Journal Article
• Authors: Shahid, Saba; Raza, Mohammad; Junejo, Samina; Maqsood, Sidra
• Other Names: Luo Guangxiang (George) guestEditor.; Ly Hinh guestEditor.; Gao Shou‐Jiang guestEditor.
• Is Part Of: Journal of medical virology. Volume 93:Issue 10(2021)
• Page Start: 5988
• Page End: 5997
• Publication Date: 2021-07-14
• Subjects: COVID‐19 -- infections -- interleukin‐6 -- multisystem inflammatory syndrome (MIS‐C) -- pandemics -- pediatrics -- tertiary healthcare; Virology -- Periodicals; 616
• DOI: 10.1002/jmv.27178
• Languages: English
• ISSNs: 0146-6615

Abstract

Abstract: : As the coronavirus disease 2019 (COVID‐19) pandemic continues to evolve, differences in epidemiological and clinical features among pediatrics have been noticed across different countries. We describe the spectrum of COVID‐19 in pediatric patients treated in tertiary health care. We conducted a retrospective chart review of pediatric patients admitted to Indus Hospital & Health care network, Korangi campus, Karachi; from April 1st, 2020 to July 31st, 2020. A total of 141 COVID‐19 cases were reported, males were 81 (57%) and the median age was 8 (0.3–17) years. Moderate and severe infections were noted in 36(26%), and 17(12%) children respectively. Fever (50%) was the most common clinical feature. The SF ratio less than 264 was significantly associated with severe disease ( p < .05). Lab investigations that differed significantly across disease severity groups included IL‐6 levels ( p < .01) and Prothrombin time ( p < .05). Majority of children were advised home isolation 89 (63%), 29 (20.5%) were admitted while mortality was observed in 10 (7%) children. No significant difference was observed between children with and without malignancy. Pre‐existing comorbidities are significantly associated with COVID‐19 infections among children. Reduced SF ratio, elevated Prothrombin time, and interleukin‐6 levels are associated with greater disease severity.